Hyperpigmentation Treatment Market By Treatment Type, By Disorder Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The global hyperpigmentation treatment market was valued at $5.1 billion in 2022, and is projected to reach $10.5 billion by 2032, growing at a CAGR of 7.5% from 2023 to 2032. Hyperpigmentation is a dermatological condition characterized by the darkening or discoloration of certain areas of the skin. This phenomenon occurs when an excess amount of melanin, the pigment responsible for skin color, is produced and deposited in the skin. There are various causes of hyperpigmentation such as Melasma, sun exposure, post inflammatory hyperpigmentation, and age factor. Effective management of hyperpigmentation often involves the use of topical treatments, laser therapy, or chemical peels, along with diligent sun protection to prevent further exacerbation of the condition

Hyperpigmentation Treatment Market - IMG1

The hyperpigmentation treatment market growth is attributed to changes in beauty standards globally, and surge in geriatric population. In recent years, there has been a notable shift in societal perceptions of beauty, with an increasing emphasis on clear, even-toned skin. As a result, individuals are now more inclined toward achieving a flawless complexion, contributing to the heightened demand for hyperpigmentation treatments. The evolving beauty standards, fueled by media influence and the pervasive use of social platforms, have created a culture where blemish-free skin is considered a symbol of health and attractiveness. This cultural shift has led to a surge in the adoption of hyperpigmentation treatments as people seek effective solutions to address skin discoloration issues and attain the desired aesthetic. Thus, the change in beauty standards globally is expected to drive the growth of the hyperpigmentation treatment market.

In addition, the surge in geriatric population is expected to significantly contribute to the growth of the market. For instance, according to the U.S. Census Bureau, it was reported that the older population reached 55.8 million in 2020. As the global demographic landscape continues to evolve, with an increasing proportion of elderly individuals, the incidence of hyperpigmentation disorders becomes more prevalent. Hyperpigmentation, characterized by darkened areas of the skin, is a common dermatological concern among the elderly, often attributed to factors such as sun exposure, age-related changes, and underlying medical conditions. The geriatric population seeking solutions to enhance skin appearance and address pigmentation irregularities, has fueled the demand for advanced and targeted hyperpigmentation treatments. The pharmaceutical and skincare industries have developed innovative products and therapies specifically tailored to cater to the unique needs of the aging population. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market.

The hyperpigmentation treatment market is segmented on the basis of treatment type, disorder type, end user, and region. By treatment type, the market is classified into topical agent, photo therapy, and microdermabrasion. By disorder type, the market is divided into age spots, melasma, and others. Others include post-inflammatory hyperpigmentation and acne scars. By end user, it is segregated into hospitals, dermatological clinics, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the hyperpigmentation treatment market are Episciences Inc, Vivier Pharma, Pierre Fabre S.A, L'Oreal Paris, Areolase Corporation, Lyma, Trophy Skin, Bio Italica, PCA Skin and Procter & Gamble. Key players have adopted product launch as a key developmental strategy to improve the product portfolio of the hyperpigmentation treatment market

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperpigmentation treatment market analysis from 2022 to 2032 to identify the prevailing hyperpigmentation treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hyperpigmentation treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hyperpigmentation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Treatment Type

Topical Agent
Photo Therapy
Microdermabrasion

By Disorder Type

Age Spot
Melasma
Other

By End User

Hospitals
Dermatological clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Colombia
- Argentina
- Rest Of La
Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest Of Mea

Key Market Players:

Episciences Inc
Vivier Pharma
Pierre Fabre S.A
L'Oreal Group
Areolase Corporation
Lyma
Trophy Skin
Bio Italica
PCA Skin
Procter & Gamble

Product Code: A186336

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Topical Agent
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Photo Therapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Microdermabrasion
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Age Spot
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Melasma
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Other
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: HYPERPIGMENTATION TREATMENT MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Dermatological clinics
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: HYPERPIGMENTATION TREATMENT MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Treatment Type
- 7.2.3. Market size and forecast, by Disorder Type
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Treatment Type
  - 7.2.5.1.2. Market size and forecast, by Disorder Type
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Treatment Type
  - 7.2.5.2.2. Market size and forecast, by Disorder Type
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Treatment Type
  - 7.2.5.3.2. Market size and forecast, by Disorder Type
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Treatment Type
- 7.3.3. Market size and forecast, by Disorder Type
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Treatment Type
  - 7.3.5.1.2. Market size and forecast, by Disorder Type
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Treatment Type
  - 7.3.5.2.2. Market size and forecast, by Disorder Type
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Treatment Type
  - 7.3.5.3.2. Market size and forecast, by Disorder Type
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Treatment Type
  - 7.3.5.4.2. Market size and forecast, by Disorder Type
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Treatment Type
  - 7.3.5.5.2. Market size and forecast, by Disorder Type
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Treatment Type
  - 7.3.5.6.2. Market size and forecast, by Disorder Type
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Treatment Type
- 7.4.3. Market size and forecast, by Disorder Type
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Treatment Type
  - 7.4.5.1.2. Market size and forecast, by Disorder Type
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Treatment Type
  - 7.4.5.2.2. Market size and forecast, by Disorder Type
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Treatment Type
  - 7.4.5.3.2. Market size and forecast, by Disorder Type
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Treatment Type
  - 7.4.5.4.2. Market size and forecast, by Disorder Type
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Treatment Type
  - 7.4.5.5.2. Market size and forecast, by Disorder Type
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Treatment Type
  - 7.4.5.6.2. Market size and forecast, by Disorder Type
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. Latin America
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Treatment Type
- 7.5.3. Market size and forecast, by Disorder Type
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Treatment Type
  - 7.5.5.1.2. Market size and forecast, by Disorder Type
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Colombia
  - 7.5.5.2.1. Market size and forecast, by Treatment Type
  - 7.5.5.2.2. Market size and forecast, by Disorder Type
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. Argentina
  - 7.5.5.3.1. Market size and forecast, by Treatment Type
  - 7.5.5.3.2. Market size and forecast, by Disorder Type
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest Of La
  - 7.5.5.4.1. Market size and forecast, by Treatment Type
  - 7.5.5.4.2. Market size and forecast, by Disorder Type
  - 7.5.5.4.3. Market size and forecast, by End User
7.6. Middle East and Africa
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by Treatment Type
- 7.6.3. Market size and forecast, by Disorder Type
- 7.6.4. Market size and forecast, by End User
- 7.6.5. Market size and forecast, by country
  - 7.6.5.1. Gcc
  - 7.6.5.1.1. Market size and forecast, by Treatment Type
  - 7.6.5.1.2. Market size and forecast, by Disorder Type
  - 7.6.5.1.3. Market size and forecast, by End User
  - 7.6.5.2. South Africa
  - 7.6.5.2.1. Market size and forecast, by Treatment Type
  - 7.6.5.2.2. Market size and forecast, by Disorder Type
  - 7.6.5.2.3. Market size and forecast, by End User
  - 7.6.5.3. North Africa
  - 7.6.5.3.1. Market size and forecast, by Treatment Type
  - 7.6.5.3.2. Market size and forecast, by Disorder Type
  - 7.6.5.3.3. Market size and forecast, by End User
  - 7.6.5.4. Rest Of Mea
  - 7.6.5.4.1. Market size and forecast, by Treatment Type
  - 7.6.5.4.2. Market size and forecast, by Disorder Type
  - 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Episciences Inc
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Vivier Pharma
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Pierre Fabre S.A
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. L'Oreal Group
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Areolase Corporation
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Lyma
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Trophy Skin
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Bio Italica
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. PCA Skin
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Procter & Gamble
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments